接続ドラッグデリバリー市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、投与経路別、用途別、地域別、競合別、2020-2030年

接続ドラッグデリバリーの世界市場規模は2024年に64億5,000万米ドル、2030年には151億5,000万米ドルに達すると予測、CAGRは15.25%。

世界の接続ドラッグデリバリー市場は、高度なデジタル技術の統合、ヘルスケア提供モデルの転換、個別化されたアウトカム重視のケアの高まりによって形成され、大きな進化を遂げつつあります。組み込みセンサー、Bluetooth接続、コンパニオンモバイルアプリ、クラウドベースのアナリティクスを備えたこれらの次世代ドラッグデリバリーシステムは、服薬アドヒアランスの向上、実用的な健康インサイトの提供、特に慢性疾患管理における長期的な治療成果の改善を目的として構築されています。

ヘルスケアイノベーション、デジタルトランスフォーメーション、医薬品の進歩の結節点に位置するこの市場は、強い勢いを増しています。バイオ医薬品企業、医療技術企業、支払者、医療提供者を含むエコシステム全体の利害関係者が、遠隔モニタリングをサポートし、アドヒアランス追跡を自動化し、リアルタイムの患者関与を可能にするコネクテッド治療プラットフォームに積極的に投資しています。規制の枠組みが成熟し、デジタルヘルスの償還がより構造化されるにつれて、特に慢性疾患の負担が増大し、デジタルインフラが整備されつつある地域において、市場は急速に拡大することになります。コネクテッド・ドラッグデリバリーはもはやニッチではなく、精密医療と分散型医療提供の未来における戦略的支柱として台頭しつつあります。

市場促進要因

長期投薬が必要な慢性疾患の有病率の上昇

主な市場課題

デバイスの高コストと限られた償還支援

主要市場動向

人工知能（AI）と高度分析のコネクテッド・デバイスへの統合

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 接続ドラッグデリバリー市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品タイプ別（スタンドアロンコンポーネントとソフトウェア、統合デバイス）
  • 投与経路（非経口、吸入）
  • 用途別（喘息、COPD、糖尿病管理、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米の接続ドラッグデリバリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の接続ドラッグデリバリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域の接続ドラッグデリバリー市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米の接続ドラッグデリバリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの接続ドラッグデリバリー市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の接続ドラッグデリバリー市場：SWOT分析

第14章 競合情勢

• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S
• Phillips Medisize
• Medtronic Plc.
• Adherium Limited
• Tandem Diabetes Care, Inc.
• Biocorp Life Sciences Pvt. Ltd
• Resmed Corp
• Ypsomed AG
• AptarGroup, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Connected Drug Delivery Devices market was valued at USD 6.45 Billion in 2024 and is expected to reach USD 15.15 Billion by 2030 with a CAGR of 15.25%. The Global Connected Drug Delivery Devices Market is undergoing a significant evolution, shaped by the integration of advanced digital technologies, shifting healthcare delivery models, and the rising emphasis on personalized, outcomes-driven care. These next-generation drug delivery systems equipped with embedded sensors, Bluetooth connectivity, companion mobile apps, and cloud-based analytics are purpose-built to enhance medication adherence, deliver actionable health insights, and improve long-term treatment outcomes, particularly for chronic disease management.

Positioned at the nexus of healthcare innovation, digital transformation, and pharmaceutical advancement, this market is gaining strong momentum. Stakeholders across the ecosystem including biopharma companies, medtech firms, payers, and providers are actively investing in connected therapeutic platforms that support remote monitoring, automate adherence tracking, and enable real-time patient engagement. As regulatory frameworks mature and digital health reimbursement becomes more structured, the market is set to scale rapidly, especially in regions with growing chronic disease burdens and increasing digital infrastructure. The connected drug delivery landscape is no longer a niche it's emerging as a strategic pillar in the future of precision medicine and decentralized care delivery.

Key Market Drivers

Rising Prevalence of Chronic Diseases Requiring Long-Term Medication

The escalating global burden of chronic diseases is a primary catalyst fueling the growth of the Global Connected Drug Delivery Devices Market. Chronic diseases such as cardiovascular disorders, cancer, diabetes, and chronic respiratory illnesses now represent the primary drivers of mortality and long-term disability worldwide. These conditions account for approximately 75% of all global deaths, underscoring their disproportionate impact on both public health and economic productivity. Chronic diseases account for nearly three-quarters of global deaths and continue to rise due to aging populations, sedentary lifestyles, urbanization, and poor dietary habits.

Over 537 million adults are currently living with diabetes, a number expected to exceed 783 million by 2045. According to the Global Initiative for Asthma (GINA), asthma remains one of the most widespread chronic non-communicable diseases, impacting more than 260 million individuals globally. It is a major contributor to global morbidity and is linked to over 450,000 deaths annually. The high incidence and mortality associated with asthma reflect a persistent gap in disease control, adherence, and access to effective management tools particularly in underserved regions. This highlights a growing market opportunity for connected respiratory drug delivery solutions that can improve treatment precision, monitor patient adherence in real time, and reduce preventable asthma-related complications. These diseases often require daily or weekly medication regimens involving injectables, inhalers, or complex drug delivery protocols. This rapidly growing patient pool directly increases demand for connected devices that ensure accurate dosing, adherence tracking, and ongoing patient support.

Medication non-adherence is a major concern in chronic disease management, leading to worsening health outcomes, increased hospitalizations, and higher healthcare costs. Research consistently indicates that 40% to 60% of patients managing chronic conditions exhibit poor medication adherence, frequently skipping doses, mismanaging dosage schedules, or discontinuing treatment prematurely. Connected drug delivery devices help solve this challenge by: Providing automated reminders and alerts through mobile apps. Tracking real-time usage and sending adherence data to healthcare providers. Enabling patient engagement through visual feedback, usage history, and digital coaching. By improving adherence, these devices not only enhance clinical outcomes but also align with the priorities of healthcare payers and providers who are focused on value-based care delivery. Patients with chronic conditions often require long-term, consistent drug administration that can be managed at home without the need for frequent clinic visits. Connected drug delivery devices support this transition by enabling: Self-injection or inhalation with minimal training, even for biologics and specialty medications. Real-time feedback to ensure correct usage, minimizing the risk of administration errors. Remote data sharing with physicians, allowing for continuous therapy optimization and proactive intervention. This functionality is especially crucial for diseases like rheumatoid arthritis, multiple sclerosis, and hormone disorders, where biologics and specialty injectables are becoming the standard of care.

Key Market Challenges

High Cost of Devices and Limited Reimbursement Support

One of the most significant barriers to market expansion is the high upfront cost associated with connected drug delivery devices, especially compared to traditional drug administration methods. These devices often incorporate advanced features such as Bluetooth connectivity, integrated sensors, and cloud-based data transmission all of which increase production costs.

For healthcare providers and payers, especially in price-sensitive markets, justifying the added cost becomes challenging without a clear and quantifiable return on investment (ROI). Reimbursement frameworks remain fragmented and inconsistent across regions. In many countries, connected devices are not fully covered under public or private insurance plans, limiting patient accessibility particularly in low- and middle-income economies. Additionally, the cost of accompanying digital infrastructure (such as mobile apps, cloud platforms, and device integration with EHRs) can further complicate adoption. Until reimbursement models evolve to recognize the long-term cost savings of improved adherence and reduced hospitalizations, affordability will continue to be a limiting factor.

Key Market Trends

Integration of Artificial Intelligence (AI) and Advanced Analytics into Connected Devices

One of the most significant trends shaping the future of connected drug delivery devices is the integration of AI and real-time analytics. Modern devices are evolving from passive tracking tools into intelligent therapeutic systems capable of learning from user data and dynamically optimizing treatment regimens.

Predictive dosing algorithms can now analyze historical adherence data, biometrics (e.g., blood glucose levels), and behavioral trends to fine-tune dosage recommendations in real time. AI-driven insights allow early identification of non-compliance, adverse events, or therapy deviations, which helps healthcare providers intervene proactively. This trend is particularly impactful in chronic disease management such as diabetes and asthma, where continuous optimization of therapy enhances patient outcomes while reducing hospitalization costs. Pharmaceutical companies are increasingly partnering with digital health firms to develop smart therapeutics, combining connected devices with data-driven platforms, creating a seamless patient-provider feedback loop.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• Novo Nordisk A/S
• Phillips Medisize
• Medtronic Plc.
• Adherium Limited
• Tandem Diabetes Care, Inc.
• Biocorp Life Sciences Pvt. Ltd
• Resmed Corp
• Ypsomed AG
• AptarGroup, Inc

Report Scope:

In this report, the Global Connected Drug Delivery Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Connected Drug Delivery Devices Market, By Product Type:

• Standalone Components & Software
• Integrated Devices

Connected Drug Delivery Devices Market, By Route of Administration:

• Parenteral
• Inhalational

Connected Drug Delivery Devices Market, By Application:

• Asthma
• COPD
• Diabetes Management
• Others

Connected Drug Delivery Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Connected Drug Delivery Devices Market.

Available Customizations:

Global Connected Drug Delivery Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Connected Drug Delivery Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Standalone Components & Software, Integrated Devices)
  • 5.2.2. By Route of Administration (Parenteral, Inhalational)
  • 5.2.3. By Application (Asthma, COPD, Diabetes Management, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Connected Drug Delivery Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Route of Administration
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Connected Drug Delivery Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Route of Administration
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Connected Drug Delivery Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Route of Administration
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Connected Drug Delivery Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Route of Administration
      • 6.3.3.2.3. By Application

7. Europe Connected Drug Delivery Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Route of Administration
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Connected Drug Delivery Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Connected Drug Delivery Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Application
  • 7.3.3. Italy Connected Drug Delivery Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Application
  • 7.3.4. France Connected Drug Delivery Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Route of Administration
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Connected Drug Delivery Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Route of Administration
      • 7.3.5.2.3. By Application

8. Asia-Pacific Connected Drug Delivery Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Route of Administration
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Connected Drug Delivery Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Application
  • 8.3.2. India Connected Drug Delivery Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Application
  • 8.3.3. Japan Connected Drug Delivery Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Application
  • 8.3.4. South Korea Connected Drug Delivery Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Application
  • 8.3.5. Australia Connected Drug Delivery Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Application

9. South America Connected Drug Delivery Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Route of Administration
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Connected Drug Delivery Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Connected Drug Delivery Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Connected Drug Delivery Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Application

10. Middle East and Africa Connected Drug Delivery Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Route of Administration
  • 10.2.3. By Application
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Connected Drug Delivery Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Connected Drug Delivery Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Connected Drug Delivery Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Connected Drug Delivery Devices Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Teva Pharmaceutical Industries Ltd.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Novo Nordisk A/S
• 14.3. Phillips Medisize
• 14.4. Medtronic Plc.
• 14.5. Adherium Limited
• 14.6. Tandem Diabetes Care, Inc.
• 14.7. Biocorp Life Sciences Pvt. Ltd
• 14.8. Resmed Corp
• 14.9. Ypsomed AG
• 14.10.AptarGroup, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer